Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
RATIONALE-301
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- NCT03412773 ↗
- Completed
- BeiGene
- Standard
We haven't built an HCP commentary report on RATIONALE-301 (tislelizumab in first-line unresectable hepatocellular carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RATIONALE-301 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 13 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Tislelizumab; Sorafenib
- Arms
- Safety Run-In Sub-study · Experimental
- Arm A: Tislelizumab · Experimental
- Arm B: Sorafenib · Active comparator
- Enrollment
- 684
- Primary outcomes
- Safety Run-in Sub-study: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Safety Run-in Sub-study: Serum Concentration of Tislelizumab
- Main Study: Overall Survival (OS)
- Sponsor
- BeiGene
- Start
- Dec 18, 2017
- Primary completion
- Jul 11, 2022
- Results posted
- Yes
- Registry record
- NCT03412773 · updated Oct 14, 2025
Publications
linked from the registry- Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 2019 Jun;15(16):1811-1822. doi: 10.2217/fon-2019-0097. Epub 2019 Apr 10. PubMed 30969136
- Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, Satoh T, Marino D, Assenat E, Li S, Chen Y, Boisserie F, Abdrashitov R, Finn RS, Vogel A, Zhu AX. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Dec 1;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003. PubMed 37796513
- Finn RS, Kudo M, Barnes G, Meyer T, Boisserie F, Abdrashitov R, Chen Y, Li S, Zhu AX, Qin S, Vogel A. Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study. Liver Cancer. 2024 Feb 21;13(5):548-560. doi: 10.1159/000537966. eCollection 2024 Oct. PubMed 39435268